Orchid Cellmark's Q1 Revenues Inch Up as UK Gains Offset by Lower US Sales | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Orchid Cellmark today reported that its first-quarter revenues inched up around 1 percent, while its net loss jumped 67 percent.

The Princeton, NJ-based firm had total revenues of $14.1 million for the three-month period ended March 31, compared to $14 million in revenues for the first quarter of 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.